IP Library › Patent Application 16741202

Patent Application

App. No. 16/741,202

T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US None
App. No.: 16/741,202

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

Claims (107)

1 .- 132 . (canceled)

133 . A molecule comprising:

a) a first polypeptide comprising:

i) an HPV16 cancer-associated peptide epitope; and

ii) first class I major histocompatibility complex (MHC) polypeptide;

b) a second polypeptide comprising a second class I MHC polypeptide; and

c) one or more immunomodulatory polypeptides,

wherein the first and second polypeptide form a heterodimer,

wherein the first and/or the second polypeptide comprises the one or more immunomodulatory polypeptides,

wherein the one or more immunomodulatory polypeptides comprises one or more variant interleukin-2 (IL-2) polypeptides comprising an amino acid sequence having at least 85% amino acid sequence identity to set forth in SEQ ID NO:1, and having one or more amino acid substitutions relative to set forth in SEQ ID NO:1, and

wherein at least one of the one or more immunomodulatory polypeptides that is a variant IL-2 polypeptide exhibits reduced binding affinity to an IL-2 receptor (IL2R) comprising alpha, beta, and gamma polypeptides having amino acid sequences set forth in SEQ ID NOs:54-56, compared to the binding affinity of a control IL-2 polypeptide comprising the IL-2 amino acid sequence set forth in SEQ ID NO:1 for the IL2R polypeptide.

134 . A composition comprising one or more nucleic acids encoding the first and second polypeptides of claim 133 .

135 . A method of producing the molecule of claim 133 , the method comprising culturing a host cell comprising a composition according to claim 134 in vitro in a culture medium under conditions such that the host cell produces the molecule.

136 . A method of activating an epitope-specific T cell, the method comprising contacting in vivo the T cell with the molecule of claim 133 , wherein said contacting activates the epitope-specific T cell.

137 . A method of activating an epitope-specific T cell, the method comprising contacting ex vivo the T cell with the molecule of claim 133 , wherein said contacting activates the epitope-specific T cell.

138 . A method of treating cancer in an individual, the method comprising administering to the individual an effective amount of the molecule of claim 133 .

139 . A method of detecting, in a mixed population of T cells obtained from an individual, the presence of a target T cell that binds an epitope of interest, the method comprising:

a) contacting in vitro the mixed population of T cells with the molecule of claim 133 , wherein the molecule comprises the epitope of interest; and

b) detecting activation and/or proliferation of target T cells in response to said contacting.

140 . A molecule comprising:

a) a first polypeptide comprising:

i) a cancer-associated peptide epitope other than an HPV16 cancer-associated epitope; and

ii) first class I major histocompatibility complex (MHC) polypeptide;

b) a second polypeptide comprising a second class I MHC polypeptide; and

c) one or more immunomodulatory polypeptides,

wherein the first and second polypeptide form a heterodimer,

wherein the first and/or the second polypeptide comprises the one or more immunomodulatory polypeptides,

wherein at least one of the one or more immunomodulatory polypeptides that is a variant IL-2 polypeptide exhibits reduced binding affinity to an IL-2 receptor (IL2R) comprising alpha, beta, and gamma polypeptides having amino acid sequences set forth in SEQ ID NOs:54-56, compared to the binding affinity of a control IL2 polypeptide comprising the IL2 amino acid sequence set forth in SEQ ID NO:1 for the IL2R polypeptide.

141 . A composition comprising one or more nucleic acids encoding the first and second polypeptides of claim 140 .

142 . A method of producing the molecule of claim 140 , the method comprising culturing a host cell comprising a composition according to claim 141 in vitro in a culture medium under conditions such that the host cell produces the molecule.

143 . A method of activating an epitope-specific T cell, the method comprising contacting in vivo the T cell with the molecule of claim 140 , wherein said contacting activates the epitope-specific T cell.

144 . A method of activating an epitope-specific T cell, the method comprising contacting ex vivo the T cell with the molecule of claim 140 , wherein said contacting activates the epitope-specific T cell.

145 . A method of treating cancer in an individual, the method comprising administering to the individual an effective amount of the molecule of claim 140 .

146 . A method of detecting, in a mixed population of T cells obtained from an individual, the presence of a target T cell that binds an epitope of interest, the method comprising:

a) contacting in vitro the mixed population of T cells with the molecule of claim 140 , wherein the molecule comprises the epitope of interest; and

b) detecting activation and/or proliferation of target T cells in response to said contacting.

147 . A molecule comprising:

a) a first polypeptide comprising:

i) a peptide epitope present in a self antigen; and

ii) first class I major histocompatibility complex (MHC) polypeptide;

b) a second polypeptide comprising a second class I MHC polypeptide; and

c) one or more immunomodulatory polypeptides,

wherein the first and second polypeptide form a heterodimer,

wherein the first and/or the second polypeptide comprises the one or more immunomodulatory polypeptides,

148 . A molecule comprising:

a) a first polypeptide comprising:

i) a pathogen-associated peptide epitope; and

ii) first class I major histocompatibility complex (MHC) polypeptide;

b) a second polypeptide comprising a second class I MHC polypeptide; and

c) one or more immunomodulatory polypeptides,

wherein the first and second polypeptide form a heterodimer,

wherein the first and/or the second polypeptide comprises the one or more immunomodulatory polypeptides,

149 . A molecule comprising:

a) a first polypeptide comprising:

i) a peptide epitope other than an epitope of a cancer-associated antigen, a self-antigen, or a pathogen-associated epitope; and

ii) first class I major histocompatibility complex (MHC) polypeptide;

b) a second polypeptide comprising a second class I MHC polypeptide; and

c) one or more immunomodulatory polypeptides,

wherein the first and second polypeptide form a heterodimer,

wherein the first and/or the second polypeptide comprises the one or more immunomodulatory polypeptides,

wherein the one or more immunomodulatory polypeptides comprises one or more interleukin-2 (IL-2) polypeptides comprising an amino acid sequence having at least 85% amino acid sequence identity to set forth in SEQ ID NO:1, and having one or more amino acid substitutions relative to set forth in SEQ ID NO:1, and

150 . A molecule comprising:

a) a first polypeptide comprising:

i) a cancer-associated peptide epitope; and

ii) first class II major histocompatibility complex (MHC) polypeptide;

b) a second polypeptide comprising a second class II MHC polypeptide; and

c) one or more immunomodulatory polypeptides,

wherein the first and second polypeptide form a heterodimer,

wherein the first and/or the second polypeptide comprises the one or more immunomodulatory polypeptides,

151 . A molecule comprising:

a) a first polypeptide comprising:

i) a peptide epitope present in a self antigen; and

ii) first class II major histocompatibility complex (MHC) polypeptide;

b) a second polypeptide comprising a second class II MHC polypeptide; and

c) one or more immunomodulatory polypeptides,

wherein the first and second polypeptide form a heterodimer,

wherein the first and/or the second polypeptide comprises the one or more immunomodulatory polypeptides,

152 . A molecule comprising:

a) a first polypeptide comprising:

i) a pathogen-associated peptide epitope; and

ii) first class II major histocompatibility complex (MHC) polypeptide;

b) a second polypeptide comprising a second class II MHC polypeptide; and

c) one or more immunomodulatory polypeptides,

wherein the first and second polypeptide form a heterodimer,

wherein the first and/or the second polypeptide comprises the one or more immunomodulatory polypeptides,

153 . A molecule comprising:

a) a first polypeptide comprising:

i) a peptide epitope other than an epitope of a cancer-associated antigen, a self-antigen, or a pathogen-associated epitope; and

ii) first class II major histocompatibility complex (MHC) polypeptide;

b) a second polypeptide comprising a second class II MHC polypeptide; and

c) one or more immunomodulatory polypeptides,

wherein the first and second polypeptide form a heterodimer,

wherein the first and/or the second polypeptide comprises the one or more immunomodulatory polypeptides,

Assignments (1)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2020

From: SEIDEL, RONALD D., III; CHAPARRO, RODOLFO J.

To: CUE BIOPHARMA, INC.

Reel/Frame 052953/0086 →